Abstract
Get full access to this article
View all access options for this article.
References
1.
Steiner
M
,
Macdougall
M
,
Brown
E.
The premenstrual symptoms screening tool (PSST) for clinicians . Arch Womens Ment Health . 2003 ;6 :203 –209 .
2.
Baker
LJ
,
O'Brien
PM.
Potential strategies to avoid progestogen-induced premenstrual disorders . Menopause Int . 2012 ;18 :73 –76 .
3.
Mishell
D.
Premenstrual Disorders: epidemiology and disease burden . Am J Manag Care . 2005 ;11 : S473 –S479 .
4.Diagnostic and statistical manual of mental disorders , 5th ed. Washington, DC : American Psychiatric Association ; 2013 .
5.
Endicott
J
,
Nee
J
,
Harrison
W.
Daily Record of Severity of Problems (DRSP): reliability and validity . Arch Womens Ment Health . 2006 ;9 :41 –49 .
6.
Naranjo
CA
,
Busto
U
,
Sellers
EM
, A method for estimating the probability of adverse drug reactions . Clin Pharmacol Ther . 1981 ;30 :239 –245 .
7.Bayer HealthCare Pharmaceuticals Inc . MIRENA (levonorgestrel) intrauterine device. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=92231d6f-f4d8-43b0-aa95-f7cec1cc18c5#nlm34070-3. Accessed August 21, 2013 .
8.
Sivin
I.
Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants . Drug Saf . 2003 ;26 :303 –335 .